MDR-TB treatment centers and sub-centers in Nepal.

<p>Footnote <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0008313#pone-0008313-g001" target="_blank">Figure 1:</a> In 2005–2006, not all the health centres were functioning. The 175 cases included in this study were under care at 17 clinics (Bhaktapur, Bheri, Bir, Genetup, Haraicha, HelpHand, INF_Banke, KohalpurMC, Mahakali, Mangalbare, NATA, NMC, NTC, Patan, RTC, Stupa, and TUTH).</p

Characteristics of the study population.

<p>SD = Standard Deviation; IQR = Inter Quartile Range.</p

Treatment outcomes for MDR-TB cases by region, Nepal, 2005–2006.

<p>Treatment outcomes for MDR-TB cases by region, Nepal, 2005–2006.</p

Resistance to first-line anti-TB drugs at baseline DST.

<p>Resistance to first-line anti-TB drugs at baseline DST.</p

Months till death (N = 14, thick line) or default (N = 29, dotted line) for MDR-TB cases, Nepal, 2005–2006.

<p>Months till death (N = 14, thick line) or default (N = 29, dotted line) for MDR-TB cases, Nepal, 2005–2006.</p

Variables associated with cure.

<p>Variables associated with cure.</p

Major adverse events registered in the study cohort.

<p>Major adverse events registered in the study cohort.</p